CORONANSECORONA Remedies LimitedMinimalNeutral
Announced Fri, 22 May · 10:37 IST

CORONA Remedies Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

CORONA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-1.7%1-day move
₹1720.00
prior close
₹1685.80
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.0+0.0+0.2+0.3-1.7-0.9-2.4-2.4-2.0-0.7+0.4+7.5+18.4
Up moveDown movePending
AI summary

Nirav Mehta, Managing Director and CEO and Promoter of CORONA Remedies Limited, has submitted a declaration confirming that neither he nor any Persons Acting in Concert (PAC) have created any encumbrance (pledge) on the equity shares held by them during financial year 2025-2026. The filing lists 23 entities under the Promoter and Promoter Group category, including family members and two LLPs (NKM Nextgen LLP and KL Next Enterprise LLP). This is a nil/negative disclosure filed with both BSE and NSE.

Likely market impact

Positive signal for investors — the absence of any share pledges reduces risk of forced selling pressure and indicates the promoter group has not leveraged their holdings, which is generally viewed favourably for stock stability.